IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors

Molecular Cancer Therapeutics

Volumn 14, Issue 7, 2015, Pages 1605-1613

  Ab, Olga ^a   Whiteman, Kathleen R ^a   Bartle, Laura M ^a   Sun, Xiuxia ^a   Singh, Rajeeva ^a   Tavares, Daniel ^a   La Belle, Alyssa ^a,c   Payne, Gillian ^a   Lutz, Robert J ^b   Pinkas, Jan ^a   Goldmacher, Victor S ^a   Chittenden, Thomas ^a   Lambert, John M ^a  

^a IMMUNOGEN INC   (United States)

^b ImmunoGen   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE RECEPTOR 1; MIRVETUXIMAB; MIRVETUXIMAB SORAVTANSINE; ANTIBODY CONJUGATE; MAYTANSINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BYSTANDER EFFECT; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NUDE MOUSE; PROCEDURES; SCID MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BYSTANDER EFFECT; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICE, NUDE; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942085714     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1095     Document Type: Article

References (49)

1. Antony AC. The biological chemistry of folate receptors. Blood 1992;79:2807-20.
2. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-28.
3. Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl 1994;8:89-95.
4. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297-303.
5. O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus 2012;1:22.
6. O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012;3:414-25.
7. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93.
8. Scorer P, Lawson N, Quinn A. A full immunohistochemical evaluation of a novel monoclonal antibody to folate receptor-alpha (FR-a). Novocastra J Histopathol, Reagents 2010;3:8-12.
9. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108:619-26.
10. Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F, et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol 2013;130:192-9.
11. Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004;56:1161-76.
12. Marchetti C, Palaia I, GiorginiM, DeMedici C, Iadarola R, Vertechy L, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther 2014;7:1223-36.
13. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010;53:6811-24.
14. Pribble P, Edelman MJ. EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs 2012;21:755-61.
15. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42.
16. Serpe L, Gallicchio M, Canaparo R, Dosio F. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmgenomics Pers Med 2014;7:31-42.
17. Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, et al. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol Pharm 2009;6:1518-25.
18. Reddy JA, Bloomfield A, Nelson M, Dorton R, Vetzel M, Leamon CP. Pre-clinical development of EC1456: a potent folate targeted tubulysin SMDC [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr. 5-9; San Diego, CA. Philadelphia (PA): AACR;
19. Cancer Res 2014;74 (19 Suppl). Abstract nr 832.
20. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6.
21. Vergote I, Armstrong D, Scambia G, Fujiwara K, Gorbunova V, Schweizer C, et al. Phase 3 double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum-sensitive ovarian cancer in first relapse [abstract]. In: Proceedings of the European Society of Gynecological Oncology 18th International Meeting; 2013 Oct. 19-22; Liverpool, United Kingdom;
22. Int J Gynecol Cancer 2013;23(8 Suppl 1):11.
23. Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
24. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.
25. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
26. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9.
27. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010;9:2689-99.
28. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010;9:2700-13.
29. Kelly KR, Chanan-Khan A, Heffner LT, Somlo G, Siegel DS, Zimmerman T, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib. Blood 2014;124:4736-4736.
30. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248-62.
31. Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, et al. A doseescalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014;20:213-20.
32. Stathis A, Freedman AS, Flinn IW, Maddocks KJ, Weitman S, Berdeja JG, et al. A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2014;124:1760.
33. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408.
34. Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 2011;54:3606-23.
35. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
36. HarlowE, Lane D. Antibodies: a laboratory manual. New York: Cold Spring Harbor Laboratory; 1988.
37. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
38. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006;119:243-50.
39. Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991;51:6125-32.
40. FiginiM, Obici L, Mezzanzanica D, Griffiths A, Colnaghi MI, WinterG, et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res 1998;58:991-6.
41. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 1994;91:969-73.
42. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
43. Polson AG, WilliamsM, Gray AM, Fuji RN, Poon KA, McBride J, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010;24:1566-73.
44. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am 2012;26:1-12.
45. Zalcman G, Bergot E, Lechapt E. Update on nonsmall cell lung cancer. Eur Respir Rev 2010;19:173-85.
46. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, et al. Disulfidelinked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27.
47. Kovtun Y, Jones G, Audette C, Mayo M, Leece B, Zhao R, et al. 235 Negatively-charged sulfonate group in linker improves potency of antibody-maytansinoid conjugates against multidrug-resistant cancer cells. Eur J Cancer Supplements 2010;8:76-7.
48. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24.
49. Moore KN, Ponte J, LoRusso P, Birrer MJ, Bauer TM, Borghaei H, et al. Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 5571).